A Yahoo Finance analysis article pointed out that CRISPR Therapeutics (CRSP) stock price has only risen 8% year-to-date, significantly underperforming the 27% gain of the Nasdaq Biotechnology Index and the 12% gain of the S&P 500. Cathie Wood, through her Ark Invest ETFs, holds a significant position in CRSP with an average cost basis of $66, and with the current stock price around $52, her holdings are at a loss.
The analysis suggests that CRSP's long-term investment prospects remain strong, primarily driven by the revenue growth of its commercialized Casgevy therapy, as well as CTX611, which is about to enter phase 3 clinical trials, and nine other therapies in development. The company's second-quarter revenue was $10.2 million, compared to $892,000 in the same period last year; loss per share narrowed to $0.94, compared to $2.40 in the same period last year. Furthermore, the company's cash reserves reached $2.36 billion, a 19.2% year-over-year increase, sufficient to support its multiple clinical trials.
The U.S. Food and Drug Administration (FDA) approved Casgevy on July 1 for children aged 2 and older with sickle cell disease or transfusion-dependent beta-thalassemia, further expanding the market potential of this therapy.
Analysis indicates that despite CRISPR Therapeutics shares rising only 8% this year, Cathie Wood's bet on its gene-editing stock is not "dead money."
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Supplementary Report | Peninsula to Iran Navy Briefing on Nov 21: An oil tanker reportedly struck a mine and caught fire east of the Strait of Hormuz
-
2
Al Jazeera: Saudi-led coalition says it intercepted a Houthi ballistic missile targeting western Saudi Arabia
-
3
Bahrain strongly condemns Iranian attack, calls on UN Security Council to take decisive measures
-
4
Al Jazeera citing Turkish Foreign Minister: Israel blocks entry of thousands of container homes destined for Gaza
-
5
Lebanese President Joseph Aoun has demanded that Israel withdraw its troops from the south and condemned Iran's interference in Lebanon's internal affairs.
-
6
Wang Shi, founder of China Vanke, and Wang Jianlin, chairman of Dalian Wanda, are pivoting toward urban renewal, with a focus on existing commercial assets.
-
7
Palestinian Ministry of Health: Gaza death toll rises to 1,671 since October "ceasefire"
-
8
The Houthis have denied threatening Mecca in Saudi Arabia, stating that their operations target oil and gas facilities as well as military bases.
-
9
Musk states that Tesla's FSD V15 adopts a brand-new architecture, with the critical intervention rate improved by 25x
-
10
How to buy and sell MUNCH token? Which exchanges is MUNCH listed on?
Markets Today
Recommended Reading


